Oncolytics Biotech® Inc. nhasi yakazivisa kuburitswa kwedata rekiriniki rinoratidzira synergistic anti-cancer chiitiko chepelareorep chakasanganiswa nechimeric antigen receptor (CAR) T cell therapy mumamota akasimba. Pepa racho, rakanzi "Oncolytic virus-mediated expansion of dual-specific CAR T masero anovandudza mashandiro emumamota akasimba mumakonzo," rakaburitswa muScience Translational Medicine mukubatana nevatsvaguri vepanzvimbo dzakawanda dzine mukurumbira, kusanganisira Mayo Clinic neDuke University. Chibatanidza kune bepa chinogona kuwanikwa nekudzvanya pano.
"Kuva nemigumisiro iyi yakadhindwa mujenari repamusoro-soro rinopa humbowo hunokosha hwekunze hwekukosha kwazvo," akadaro Thomas Heineman, MD, Ph.D., Chief Medical Officer weOncolytics Biotech Inc. "Kunyange zvazvo masero eCAR T akagadzira kwenguva refu. kurapa muhematologic malignancies1, iyo immunosuppressive tumor microenvironments (TMEs) yegomarara renhengo dzakasimba kusvika parizvino dzakaganhura kushanda kwavo mune izvi zviratidzo. Pelareorep yakadzokororwa yakaratidzwa kudzosera immunosuppressive TMEs, uye mune ino chinyorwa pelareorep inoratidzwa kuti igone kushanda kwemasero eCAR T mumhando dzakawanda dzemurine dzakaoma bundu. Uku ndiko kuwana kwakasimba kwekuti, kana kushandurirwa kukiriniki, kunogona kuvandudza zvakanyanya kufungidzira kwevarwere vane akasiyana siyana akanyanya kupararira kenza nekupa inoveli uye inogona kusimba yekurapa sarudzo. Nekuratidza kugona kuvandudza T cell kutsungirira, kuderedza kupukunyuka kweantigen, uye kukunda zvinonetsa akasimba bundu TMEs, kuisirwa kwepelareorep kunogadzirisa matatu akanyanya kuomesesa migwagwa kune inoshanda CAR T kurapwa.
Andrew de Guttadauro, Mutungamiriri weOncolytics Biotech US uye Global Head weBusiness Development, akawedzera kuti, "Kunyangwe nekuchinja kurapwa kwemamwe magomarara uye kudarika bhiriyoni remadhora mukutengesa gore rapfuura, marapirwo eCAR T parizvino anongobatsira vashoma vashoma vevarwere vane hematologic. malignancies. Nezvichangoburwa izvi, isu tine humbowo hwakasimba hwekuti pelareorep inogona kuvhura kukosha kweCAR T marapirwo nekuwedzera mukana wavo wekutengesa kumusika wakakura kwazvo wevarwere vegomarara vari kurwisa mamota akasimba. "
Preclinical studies yakabudiswa mupepa yakaongorora kusimba uye kushanda kwepelareorep-yakatakura CAR T masero ("CAR / Pela therapy") mumhando dzakawanda dzemurine dzakaoma bundu. Mhedzisiro yekubatanidza CAR / Pela therapy neinotevera intravenous dose yepelareorep ("pelareorep boost") yakaongororwawo. Yakakosha data uye mhedziso kubva papepa zvinosanganisira:
• Kuramba uye kurwisa kenza kwemasero eCAR T kwakagadziridzwa zvakanyanya kana akatakurwa nepelareorep. Kuenzaniswa nechero kurapwa chete, kurapwa neCAR/Pela kurapa kwakatungamira kune zvakaverengeka zvakakosha kupona mumurine ganda uye mhando dzekenza yeuropi.
• CAR / Pela therapy inoteverwa ne pelareorep boost yakakonzera kuwedzera kushanda mumurine ganda uye kenza yeuropi mienzaniso uye tumor inoporesa mu> 80% yemakonzo akabatwa mumuenzaniso wega wega.
• Kuisa CAR T masero ne pelareoep kwakatungamirira kukuvandudzwa kwekenza cell kunanga uye kudzivirira antigen kupukunyuka mu vivo kuburikidza nekugadzira CAR T masero ane hunyambiri hunyambiri hunonangidzira yavo yakagadzirwa antigen uye yekuzvarwa T cell receptor antigen. Mhedzisiro iyi inoratidza kuti CAR/Pela therapy inogona kupa kurapa-kwenguva refu mabhenefiti kana ichienzaniswa nekurapa neCAR T maseru chete.
Dr. Matt Coffey, Mutungamiriri uye Chief Executive Officer weOncolytics Biotech Inc. uye munyori pamwe naye webepa vakati, "Iyi mibairo inonakidza muenzaniso wakanaka wekuti tiri kusimudzira sei kudyidzana nevatungamiriri vepfungwa uye masangano ekutanga ekutsvagisa kuwedzera kugona kwepelareorep. therapeutic impact. Izvi zvinotibvumira kuti tirambe takatarisana nechirongwa chedu chegomarara remazamu, izvo zvakaratidza kuti kugona kwepelareorep kusimudzira bundu T cell infiltration inotungamira mukubatana necheckpoint inhibitors mukiriniki. Izvi zvichangobva kuburitswa preclinical zvakawanikwa zvinoratidza pelareorep's synergistic mabhenefiti anowedzera kunyange kupfuura chekipoint inhibitors uye anosimbisa mukana wekuwedzera yedu inogadziriswa varwere. Sezvo isu tichitsvaga mukana uyu kuenda kumberi, tinoda kushandisa hukama nevanodzidza kana veindasitiri kuitira kuti tirambe tichiita zvinangwa zvedu zvekiriniki nemakambani nekubudirira. "
ZVOKUBVA MUNYAYA INO:
- Pelareorep yakadzokororwa yakaratidzwa kudzosera immunosuppressive TMEs, uye mune ino chinyorwa pelareorep inoratidzwa kugonesa kushanda kweCAR T masero mune akawanda murine solid solid tumor models.
- Kurodha masero eCAR T ane pelareoep kwakatungamira kukuvandudza cancer sero kunanga uye kudzivirira antigen kutiza mu vivo nekugadzira masero eCAR T ane mbiri mbiri inonangana neyakagadzirwa antigen uye yemuno T cell receptor antigen.
- Nekuratidza kugona kuvandudza T sero kutsungirira, kuderedza antigen kupukunyuka, uye kukunda yakaoma akasimba bundu TMEs, kuisirwa kwepelareorep kunogadzirisa matatu akanyanya kuomesesa migwagwa kune inoshanda CAR T kurapwa.
